Placebo + AOC 1001
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
DM1
Conditions
DM1, Muscular Dystrophies, Myotonic Dystrophy, Myotonic Dystrophy 1, Myotonic Disorders, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, Inborn, Heredodegenerative Disorders, Nervous System, Neurodegenerative Diseases
Trial Timeline
Aug 4, 2022 → Sep 10, 2025
NCT ID
NCT05479981About Placebo + AOC 1001
Placebo + AOC 1001 is a phase 2 stage product being developed by Avidity Biosciences for DM1. The current trial status is completed. This product is registered under clinical trial identifier NCT05479981. Target conditions include DM1, Muscular Dystrophies, Myotonic Dystrophy.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05479981 | Phase 2 | Completed |
Competing Products
6 competing products in DM1
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VX-670 | Vertex Pharmaceuticals | Phase 2 | 51 |
| VX-670 + Placebo | Vertex Pharmaceuticals | Phase 1/2 | 40 |
| AOC 1001 + Placebo | Avidity Biosciences | Phase 1/2 | 38 |
| AOC 1001 (del-desiran) + Placebo | Avidity Biosciences | Phase 3 | 74 |
| DYNE-101 + Placebo | Dyne Therapeutics | Phase 3 | 72 |
| DYNE-101 + Placebo | Dyne Therapeutics | Phase 1/2 | 36 |